The cervical cancer screening market is poised to reach $22 billion by 2020 from ~$15 billion in 2014, at an estimated CAGR of 7.0% from 2015 to 2020.

The report segments the cervical cancer screening market is segmented on the basis of test types, end users, and geographies. Based on test type, the cervical cancer screening market is segmented into pap tests and HPV/co tests. Among both, the HPV/co-test is estimated to grow at a higher CAGR during the forecast period. This growth can largely be attributed to the growing incidences of cervical cancer, higher consistency and effectiveness of HPV tests and co-tests that reduce the annual cost of the treatment.

On the basis end users, cervical cancer screening market is classified into hospitals, laboratories, and independent physicians’ offices and clinics. The laboratories segment accounted for the largest share in 2014, while the hospitals segment is estimated to grow at a faster rate due to the increasing volume of patients in hospitals.

On the basis of geography, the cervical cancer screening market is segmented into North America, Europe, Asia-Pacific, and Rest of the World (RoW). In 2014, North America accounted for the largest share of the cervical cancer screening market. On the other hand, Asia-Pacific is expected to register a higher growth rate during the forecast period, owing to huge investment opportunities in this region.

Growing incidences of cervical cancer among sexually active women and the increased risk of HPV infection among them and favorable government initiatives and funding to increase disease awareness are driving the cervical cancer screening market. The market will be further driven by the growing adoption and awareness towards the use of molecular diagnostic assays and kits. However, the availability of HPV vaccines, uncertain reimbursement rates, and changes in regulatory guidelines are hindering the growth of the cervical cancer screening market.

Growth of this market is driven by growth in aging female population and rising prevalence rate of cervical cancer, high incidence rate of HPV infections, increasing number of awareness programs for cervical cancer screening, and government initiatives and funding. Breakthrough products and technologies, and significant growth in the HPV test market provide new growth opportunities to players in the global market. However, Changes in regulatory guidelines for cervical cancer screening, and use of HPV vaccines are the key factors that are limiting growth of this market. In addition, uncertain reimbursement scenario is the key market challenges.

MarketsandMarkets is world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.

M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.